1. Scrip

Novartis Shows Importance Of Gene Therapy With AveXis Name Change

Swiss Major Renames AveXis As Novartis Gene Therapies

 
• By Kevin Grogan

Novartis has completed its absorption of AveXis and rebranded the acquired gene therapy specialist that developed the soon-to-be SMA blockbuster Zolgensma despite struggling to meet the data integrity standards of regulators and big pharma.

Red_Umbrella_Field
AveXis firmly under the Novartis umbrella • Source: Shutterstock

AveXis, Inc., the developer of the spinal muscular atrophy (SMA) treatment Zolgensma which was bought for $8.7bn a couple of years ago, is being rebranded as Novartis Gene Therapies, demonstrating the growing importance of the Swiss major's pipeline in that space.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Advanced Therapies